Page updated August 2, 2020
Questions on our products relevant to SARS-CoV-2 and the COVID-19 response? We have technical experts prioritized
Our principles during this pandemic have been to keep our employees safe, positively contribute to public health and to ensure business continuity. We continue with these principles, as a company dedicated to collaborating with the global scientific community to solve life science’s toughest problems, ultimately accelerating access to health.
Please see the information below for updates on our global status and actions.
Given the criticality of our products and services for human health and scientific progress, we are proud of our teams who have continued to develop, manufacture, package and ship products, or provide services at our sites since the onset of the pandemic.
Our global manufacturing sites are all operating, although capacity and local conditions are variable, and each of our sites is continuing to manage business continuity plans with pandemic situational scenarios.
Employee Health and Safety:
In select regions, in accordance with local government guidance, employees are also returning to offices with precautionary measures in place.
We continue to monitor the evolving situation on a local basis with the support of data-driven dashboards, and have taken the following actions to mitigate exposure and spread of the virus:
Our global COVID-19 Task Force actively evaluates our overall supply chain, both of our products and raw material suppliers, to mitigate risk and supply disruption.
Our Life Science supply chain is composed of more than 300,000 products, across 55 manufacturing sites and 100 distribution points, and the majority of our portfolio areas have stable inventory levels to support orders. We have determined options for alternative sources, if required.
Across our overall network, our business continuity plans have been successful in:
Although we do not see significant elevated risk to our overall network, we do recognize that some sites and portfolio areas have variability in capacity, output, and transportation impacts.
COVID-19 has initiated unprecedented demand as some of our customers race to develop vaccines and treatments, as well as continue the production of non-COVID-19 lifesaving and enhancing drugs.
We have clear allocation principles for the relevant products and services supporting COVID-19, as well as critical life-saving or preventative therapeutics outside of COVID-19. Using these principles, our COVID-19 Response Team will prioritize supply, based on multiple, strategic factors that positively support public health.
We are also accelerating investments at key sites while adjusting planned production schedules for some high demand products, in order to fulfill unprecedented demand.
As regions across the globe recover and reopen, our dedicated import and export teams continue monitoring all available trade lanes to optimize transportation activities. Limited air transportation continues to create some delays with the inter-company transportation of our goods, but overall, we have not seen this significantly impact our service levels.
Predictability and stability of global transportation continues to improve, and we will maintain diligence in monitoring backlog and using all available trade lanes to prevent disruption.
Throughout the pandemic we’ve recognized the imperative nature of keeping our systems and installed equipment in Hospitals and Clinical settings, Testing Labs, Pharma and Biotech operative and serviced. We continue to review service needs, leverage virtual meetings and digital instrument connectivity to continue critical service across the globe.
We have regional guidance and processes created for visiting customer labs and offices that have reopened. Our first principle and priority of keeping our employees safe remains, so our teams are working to continue collaborating with creative, socially distanced formats and continue to leverage virtual meeting technology.